- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Do investors value the FDA orphan drug designation? ; volume:12 ; number:1 ; day:19 ; month:6 ; year:2017 ; pages:1-6 ; date:12.2017
Orphanet journal of rare diseases ; 12, Heft 1 (19.6.2017), 1-6, 12.2017
- Keyword
-
Arzneimittelentwicklung
Arzneimitteldesign
- Creator
-
Miller, Kathleen L.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13023-017-0665-6
- URN
-
urn:nbn:de:1111-201709105841
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Miller, Kathleen L.
- SpringerLink (Online service)
Other Objects (12)
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Health technology assessment: oncology drugs with orphan designation as an example
FDA
FDA
FDA
FDA
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
Establishing medical plausibility in the context of orphan medicines designation in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
The Orphan
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Health technology assessment: oncology drugs with orphan designation as an example
FDA
FDA
FDA
FDA
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
Establishing medical plausibility in the context of orphan medicines designation in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union
The Orphan
The drug development pipeline for glioblastoma: a cross sectional assessment of the FDA orphan drug product designation database
Health technology assessment: oncology drugs with orphan designation as an example
FDA
FDA
FDA
FDA
Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy
FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development
Evolving prevalence of haematological malignancies in orphan designation procedures in the European Union
Establishing medical plausibility in the context of orphan medicines designation in the European Union
Use of biomarkers in the context of orphan medicines designation in the European Union